Biophysical evaluation of cardiolipin content as a regulator of the membrane lytic effect of antimicrobial peptides.
Hernández-Villa. Laura L; Manrique-Moreno. Marcela M; Leidy. Chad C; Jemioła-Rzemińska. Małgorzata M; Ortíz. Claudia C; Strzałka. Kazimierz K
Key Findings
- Staphylococcus aureus naturally contains about 20% cardiolipin in its membrane under normal growth conditions.
- Higher cardiolipin levels (up to 40%) reduce the ability of LL‑37 and a related peptide (ΔM2) to cause membrane leakage in model liposomes.
- Cardiolipin does not change how strongly the peptides bind to the membrane; it only blocks the lysis step.
Practical Outcomes
- For biohackers using LL‑37 as a supplement for immune or skin health, this research suggests that some bacteria may be less vulnerable to LL‑37 if they increase cardiolipin in their membranes. It highlights the potential need for combination approaches that disrupt bacterial membrane composition or stress responses, rather than relying on LL‑37 alone.
Summary
The study shows that a bacterial lipid called cardiolipin can make the antimicrobial peptide LL‑37 less able to break open bacterial cells, even though LL‑37 still sticks to the bacteria. This means that some bacteria can protect themselves against LL‑37 by changing their membrane makeup.
Abstract
Cardiolipin is an anionic tetra-acyl chained glycerophospholipid that increases lipid packing levels and induces intrinsic negative curvature in membranes. Cardiolipin is found in Staphylococcus aureus (S. aureus) membranes, where increased levels of this lipid are induced at the expense of diacyl phosphatidylglycerol in response to stress. We investigate cardiolipin as an inhibitor of the lytic activity of the cationic antimicrobial peptides LL-37 and ∆M2 in model systems with varying phosphatidylglycerol/cardiolipin ratios. Using HPTLC, we show that S. aureus (RN4220), under different growth conditions, has a phosphatidylglycerol/cardiolipin ratio of 80:20. From this, we chose three model systems to evaluate (100:0, 80:20, 60:40). ∆M2 presents higher binding affinity towards all mixtures compared to LL-37. This correlates with the higher antimicrobial activity of ∆M2 compared to LL-37 in S. aureus (MIC90 of 14 μM for ∆M2 and 57.7 μM for LL-37). Laurdan GP shows that Cardiolipin decreases lipid headgroup spacing. We find that cardiolipin does not affect ∆M2 or LL-37 binding to phosphatidylglycerol/cardiolipin liposomes. Instead, cardiolipin inhibits the ability of both peptides to induce calcein leakage in model liposomes. In conclusion, cardiolipin can reduce cAMP activity by inhibiting lysis but not binding.
Study Information
pubmed
2018
2018-04-13T00:00:00.000Z
10.1016/j.bpc.2018.04.001
34
63